EPHA2 and osteosarcoma: In particular, in both osteosarcoma PDX models, we showed EphA2 expression and phosphorylation at critical serine 897 (Ser897) residue, as a sign of oncogenic, non-canonical EphA2 pathway activation [14,15,16,47].